Corporate History

April 2001

Founded in Shiba, Minato-ku, Tokyo to contribute to research and development of anti-cancer medicine, cancer therapy and cancer diagnosis based on oncogenes and proteins.

May 2001

Commenced collaboration with the Institute of Medical Science, University of Tokyo.

November 2001

Head office moved to Shiroganedai, Minato-ku, Tokyo.

October 2002

Opened research laboratory at the same place as head office in Minato-ku, Tokyo.

December 2003

Listed on the Tokyo Securities Exchange Mothers Index.

March 2005

Head office and head office laboratory facilities moved to Takatsu-ku, Kawasaki city, Kanagawa prefecture, and opened Drug Discovery Laboratory at the same address.

June 2006

Founded Vaccine Science Inc., consolidated subsidiary company of OTS, to develop peptide vaccines.

September 2007

Associated company Immunas Pharma, Inc. becomes a consolidated subsidiary of OTS through its stock acquisition.

September 2007

Merged with consolidated subsidiary company Vaccine Science Inc.

May 2010

Established Laboratoires OncoTherapy Science France S.A.R.L., a consolidated subsidiary, to contribute in research and development of anti-cancer medicine such as antibody medicine in France.

July 2017

Established Cancer Precision Medicine, Inc., a consolidated subsidiary which will conduct the genome analysis of cancer, liquid biopsy, and development of new immunotherapy including the neoantigen prediction.

August 2017

Cancer Precision Medicine, Inc. changed a corporate joint venture with OncoTherapy Science, Inc. and Theragen Etex Co., Ltd..

October 2017

Company Split Tumor Immunology Dept. from OncoTherapy Science, to Cancer Precision Medicine, Inc.

December 2017

Opened Clinical Lab. of Cancer Precision Medicine, Inc..

back to top